📧 Communication

This document is page 91 of a Cowen Collaborative Insights investment report dated February 25, 2019. It details the clinical trial results and investor analysis for the drug Epidiolex, specifically focusing on its efficacy in treating seizures (Dravet and LGS) with and without the concomitant use of clobazam, and noting that the drug is effective on its own. While part of a document production marked 'HOUSE_OVERSIGHT', the content is strictly pharmaceutical financial analysis and does not mention Jeffrey Epstein directly.